SF0166( SF 0166 | SF-0166 )

Catalog No. M12385 CAS No. 1621332-91-9

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

SF0166
Note

Research use only, not for human use.
Brief Description

SF0166 is a topically administered αvβ3 integrin antagonist, inhibits integrin-ligand interactions with IC50 of 0.6 nM to 13 nM for human αvβ3, αvβ6, and αvβ8.
Description

SF0166 is a topically administered αvβ3 integrin antagonist, inhibits integrin-ligand interactions with IC50 of 0.6 nM to 13 nM for human αvβ3, αvβ6, and αvβ8; inhibits cellular adhesion to vitronectin across human, rat, rabbit, and dog cell lines with IC50 of 7.6 pM-76 nM; significantly decreases neovascularization in the oxygen-induced retinopathy mouse models.Other Indication Phase 2 Clinical.
In Vitro

——
In Vivo

Animal Model:Female 129SVE newborn mice with oxygen-induced retinopathy (OIR) modelsDosage:5% SF0166 Administration:Bilateral eye topical drip 5% SF0166 Result:Reduced new blood vessel formation.
Synonyms

SF 0166 | SF-0166
Pathway

Cell Cycle/DNA Damage
Target

Integrin
Recptor

Integrin
Research Area

Other Indications
Indication

Other Disease

CAS Number

1621332-91-9
Formula Weight

475.497
Molecular Formula

C23H27F2N5O4
Purity

>98% (HPLC)
Solubility

——
SMILES

O=C(O)C[C@@H](C1=CC=C(OC(F)F)N=C1)N2CCN(CCCC3=NC4=C(CCCN4)C=C3)C2=O
Chemical Name

(S)-3-(6-(difluoromethoxy)pyridin-3-yl)-3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid

1. Askew BC, et al. J Pharmacol Exp Ther. 2018 May 31. pii: jpet.118.248427.

Calculator

molnova catalog